StockTipsArenaBeta

BUY Biocon Ltd — Axis Securities

BUYBiocon Ltd
Biocon share price target & all analyst calls

byAxis SecuritiesHorizon: NA (inferred 1 year)16 Feb 2026via Institutional / Brokerage Research

Entry₹380.35Inferred
Target₹435
Total upside +14.37% (call closed)
Stop lossNot given
Exit₹43519 May 2026, 12:05 pm
Target hit+14.37%0.00%upside left
Follow Axis Securities for new calls(70% target hit, 813 closed calls)Get alertsWatch BIOCON for new buy/sell callsGet alertsSee 10 active Long-term calls on BIOCON

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 26 Oct, 12:40 am IST
6 supporting3 neutral1 opposing
Supports the BUY call (6)

Outcome of Board Meeting regarding Change in Long Term Incentive Plan.

BSE · Company Update·7 May · 2w ago

(opens in new tab)

Outcome of Board Meeting regarding acquisition of equity shares of BBL.

BSE · Company Update·7 May · 2w ago

(opens in new tab)

Biocon reported Q4FY26 total income of Rs 4,569 Cr, EBITDA at Rs 1,073 Cr, and Net Profit (before exceptional items) at Rs 179 Cr. FY26 figures were Rs 17,270 Cr, Rs 3,798 Cr, and Rs 436 Cr respective

NSE · Press Release·7 May · 2w ago

(opens in new tab)

Outcome of Board Meeting held on May 07, 2026 regarding Acquisition.

NSE · Outcome of Board Meeting·7 May · 2w ago

(opens in new tab)

Biocon Limited received Health Canada approval for Bosulif (Denosumab) and Vevzuo (Denosumab), biosimilars to Prolia® and Xgeva®.

NSE · Press Release·21 Apr · 4w ago

(opens in new tab)
Neutral / worth noting (3)

Biocon Limited's Board of Directors approved audited financial results for the quarter and year ended March 31, 2026, recommended a final dividend of 10% (Re. 0.50 per share), and recommended the appo

NSE · Outcome of Board Meeting·7 May · 2w ago

(opens in new tab)

Biocon Limited's Board of Directors approved the audited financial results for the quarter and year ended March 31, 2026, and recommended a final dividend of 10% (Re. 0.50 per share). The Board also r

NSE · Outcome of Board Meeting·7 May · 2w ago

(opens in new tab)

Biocon Limited announced its audited financial results for the quarter and year ended March 31, 2026. The company also recommended a final dividend of 10% (Re. 0.50 per equity share).

NSE · Outcome of Board Meeting·7 May · 2w ago

(opens in new tab)
Weighs against the BUY call (1)

2 other SEBI-registered advisors have active long-term SELL calls on this stock

Advisor consensus · same horizon·14 Nov · 6mo ago

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Biocon

All analyst calls on Biocon

More from Axis Securities

Every call and its outcome